Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifampicin and albendazole combinations for onchocerciasis in areas co-endemic with loiasis
ISRCTN38954299Phase 2Completed
- Sponsor
- University of Buea
- Start
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of rifampicin, albendazole, doxycycline and ivermectin in onchocerciasis and loiasis (10 arms), sponsored by University of Buea. Primary endpoint: Adult female worm embryogenesis. Started Feb 2024; status: completed.
02
Drugs
rifampicinalbendazoledoxycyclineivermectin
03
Conditions
onchocerciasisloiasis
Beyond the preview
Go deeper on ISRCTN38954299.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN38954299.